ArticleChemistry & biodiversity2026
A Discovery in Compatibility of Traditional Chinese Medicine: Spatholobus suberectus Dunn Suppresses Tripterygium wilfordii Hook. f.-Induced Main Toxicity and Enhances Its Main Efficacy.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tripterygium wilfordii Hook. f. (LGT) is commonly used in the treatment of rheumatoid arthritis, but its clinical application is limited by severe hepatotoxicity. Proper compatibility contributes to toxicity reduction and efficacy enhancement. Chinese Materia Medica textbooks record that compatibility with Spatholobus suberectus Dunn (JXT) can prevent the adverse effects of LGT. Nevertheless, the detoxification effect and underlying mechanism of compatibility with JXT in LGT-induced hepatotoxicity are still unclear. First, the detoxification effect of JXT was evaluated through serum biochemical indicators and liver histopathology. Additionally, the attenuation mechanism was elucidated. The anti-inflammatory and analgesic efficacy of LGT, after compatibility with JXT, was evaluated. Moreover, the main toxic component triptolide (TP) of LGT and the main active components of JXT were detected by high-performance liquid chromatography (HPLC). Our findings revealed that compatibility with JXT significantly reduced serum levels of biochemical indicators and alleviated histopathological damage. Notably, the mRNA and protein expression levels of vascular endothelial growth factor A (VEGFA) and Flt-1 were significantly downregulated. Moreover, compatibility with JXT enhanced the anti-inflammatory and analgesic efficacy of LGT, while also reducing TP content. In conclusion, compatibility with JXT reduced LGT-induced hepatotoxicity and potentiated its anti-inflammatory and analgesic efficacy. The underlying attenuation mechanism might involve inhibiting VEGFA/Flt-1 signaling and reducing TP content.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.